Pfizer’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
Pfizer's AGMB Position: Q3 2026 in Review
Pfizer increased its AgomAb Therapeutics NV (AGMB) stake by 2,768% in Q3 2026, buying an estimated $26.9M and bringing the position to 2,151,213 shares worth $22.6M. The position accounts for 13.77% of the portfolio, ranked #4.
Pfizer first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- Pfizer held 2,151,213 shares of AgomAb Therapeutics NV worth $22.6M as of Q3 2026.
- Pfizer bought 2,076,213 AgomAb Therapeutics NV shares in Q3 2026, an estimated $26.9M.
- AgomAb Therapeutics NV made up 13.77% of Pfizer's portfolio in Q3 2026, its #4 holding.
- Pfizer first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on Pfizer's 13F filing for Q3 2026, filed 12 Nov 2026.